BioCentury | May 4, 2020
Product Development

Investors see little value in remaining Newron programs following Rett syndrome failure

...an add-on therapy to antipsychotics, and as add-on therapy for patients who are resistant to clozapine...
BioCentury | Oct 31, 2018
Distillery Therapeutics

Neurology

...paraventricular thalamic nucleus to selectively inhibit neurons projecting into the nucleus, and systemic dosing of clozapine-N-oxide...
...system decreased cocaine seeking behavior after one week of abstinence compared with empty vector plus clozapine-N-oxide...
BioCentury | Aug 1, 2018
Distillery Techniques

Drug platforms

...II α (CAMK2A) promoter that limits receptors expression to excitatory neurons, plus the hM4Di ligand clozapine-N-oxide...
BioCentury | Jul 31, 2018
Translation in Brief

ATAC of the DREADDs

...release and neuron firing in a dose-dependent manner when it binds its metabolically inactive ligand, clozapine-N-oxide...
...are critical for memory formation -- and then compared the administration of clozapine-N-oxide and vehicle. Clozapine-N-oxide...
BioCentury | May 25, 2018
Preclinical News

Activating astrocytes to enhance memory

...of the brain to express an engineered receptor that increases astrocyte activity in response to clozapine-N-oxide...
BioCentury | Dec 6, 2016
Distillery Techniques

Imaging

...TECHNOLOGY: PET A clozapine-based PET imaging agent that binds DREADD-expressing neurons could help monitor the engraftment...
...engraftment of neuronal transplants for neurological diseases. The PET agent consisted of 11 C radionuclide-labeled clozapine-N-oxide...
...2016 doi: 10.1523/JNEUROSCI.1279-16.2016 CONTACT: Makoto Higuchi, National Institute Of Radiological Sciences, Chiba, Japan email: mhiguchi@nirs.go.jp Esme Gaisford clozapine Muscarinic...
BioCentury | Apr 11, 2016
Regulation

Tolerable uncertainty

...of PDP patients pooled across the previous Nuplazid studies and the U.S. Parkinson Study Group clozapine...
BioCentury | Mar 3, 2016
Distillery Therapeutics

Therapeutics: An undetermined target

...mouse model of PD than in normal mice. In the model, clozapine N-oxide - a clozapine...
...pump. Next steps could include testing inhibitors of thalamostriatal terminals in other models of PD. Clozapine...
BioCentury | Jul 13, 2015
Company News

Oncothyreon, Braeburn deal

...granted Braeburn rights to develop and commercialize ATI-9242, a next-generation atypical antipsychotic agent modeled on clozapine...
BioCentury | Dec 15, 2014
Finance

Avanir Chronicles

...$4M in cash, $25M in notes, and up to $40M in milestones, gaining marketed antipsychotic FazaClo...
...deal with Novartis AG (NYSE:NVS; SIX:NOVN) to develop macrophage migratory inhibitor compounds.N. 7/3/07 - Sells FazaClo...
Items per page:
1 - 10 of 71